Opko Health (NASDAQ:OPK) Releases Earnings Results, Misses Expectations By $0.02 EPS

Opko Health (NASDAQ:OPK) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.02), Briefing.com reports. Opko Health had a negative net margin of 30.98% and a negative return on equity of 14.19%. The firm had revenue of $228.80 million for the quarter, compared to analysts’ expectations of $225.40 million. During the same period last year, the company posted ($0.05) earnings per share. The business’s revenue for the quarter was down 8.4% compared to the same quarter last year.

OPK stock traded down $0.04 during trading on Friday, hitting $1.47. 7,800,774 shares of the stock traded hands, compared to its average volume of 4,798,398. Opko Health has a 1 year low of $1.33 and a 1 year high of $3.93. The firm’s 50 day moving average is $1.90 and its two-hundred day moving average is $2.02. The stock has a market cap of $960.34 million, a price-to-earnings ratio of -5.88 and a beta of 2.17. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.21 and a quick ratio of 1.04.

In other news, Director Richard C. Pfenniger, Jr. acquired 25,000 shares of the business’s stock in a transaction that occurred on Friday, October 25th. The shares were bought at an average cost of $1.45 per share, with a total value of $36,250.00. Following the transaction, the director now owns 275,000 shares of the company’s stock, valued at approximately $398,750. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Phillip Md Et Al Frost acquired 50,000 shares of the business’s stock in a transaction that occurred on Thursday, October 31st. The shares were purchased at an average cost of $1.43 per share, for a total transaction of $71,500.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $4,388,599.93. The disclosure for this purchase can be found here. Insiders have purchased a total of 3,040,000 shares of company stock worth $4,545,750 over the last three months. 42.25% of the stock is currently owned by insiders.

Several analysts recently commented on OPK shares. ValuEngine raised shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Barrington Research reissued a “buy” rating and set a $4.00 price objective on shares of Opko Health in a research report on Thursday, September 12th. BidaskClub downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Tuesday, October 29th. Finally, Zacks Investment Research raised shares of Opko Health from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research report on Friday, October 18th.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Further Reading: How is the LIBOR rate calculated?

Earnings History for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.